Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis

Fig. 1

MASLD correlates with PDAC and accelerates liver metastasis. a Kaplan-Meier estimates of MASLD in Control (n = 3834) and MASLD (n = 100) populations. b The proportion of MASLD in patients with primary PDAC or liver metastasis in BJ cohort. c Representative non-contrast and contrast-enhanced CT from metastatic PDAC patients with or without MASLD in QD cohort. Hepatic metastases were indicated by the red arrows. d, e Probability of liver-specific progression-free survival in QD cohort and BJ cohort

Back to article page